共 50 条
- [41] Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 AntibodiesCANCERS, 2021, 13 (16)Bellastella, GiuseppeCarbone, CarlaScappaticcio, LorenzoCirillo, PaoloTroiani, TeresaMorgillo, FlorianaVietri, Maria TeresaDella Corte, Carminia MariaDe Falco, VincenzoNapolitano, StefaniaMaiorino, Maria IdaDe Bellis, AnnamariaEsposito, Katherine
- [42] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodiesDRUG DISCOVERY TODAY, 2015, 20 (09) : 1127 - 1134Borch, Troels H.Donia, MarcoAndersen, Mads H.Svane, Inge M.
- [43] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapyJOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346Schaberg, Kurt B.Novoa, Roberto A.Wakelee, Heather A.Kim, JinahCheung, ChristineSrinivas, SandhyaKwong, Bernice Y.
- [44] Development of novel combination cancer immunotherapy using anti-PD-1 and anti-PD-L1 antibodyCANCER SCIENCE, 2021, 112 : 741 - 741Hasegawa, HirotakaSugiyama, DaisukeKanda, MitsuroHayashi, MasamichiTanaka, ChieYamada, SuguruNakayama, GoroKoike, MasahikoNomoto, ShujiFujiwara, MichitakaKodera, YasuhiroNishikawa, Hiroyoshi
- [45] Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 AntibodiesCANCER RESEARCH, 2015, 75 (14) : 2928 - 2936Heskamp, SandraHobo, WillemijnMolkenboer-Kuenen, Janneke D. M.Olive, DanielOyen, Wim J. G.Dolstra, HarryBoerman, Otto C.
- [46] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumabSCIENTIFIC REPORTS, 2017, 7Lee, Hyun TaeLee, Ju YeonLim, HeejinLee, Sang HyungMoon, Yu JeongPyo, Hyo JeongRyu, Seong EonShin, WooriHeo, Yong-Seok
- [47] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumabScientific Reports, 7Hyun Tae LeeJu Yeon LeeHeejin LimSang Hyung LeeYu Jeong MoonHyo Jeong PyoSeong Eon RyuWoori ShinYong-Seok Heo
- [48] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in MalignanciesJOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S451Sun, J.Yang, Q.Chen, M.Gu, J.Zheng, L.Yu, Y.Li, F.Zhang, L.Niu, K.
- [49] DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCCCURRENT CANCER DRUG TARGETS, 2021, 21 (10) : 849 - 859Wei, JinhuanLu, JunCao, YunYao, GaoshengHuang, YongZhao, HongweiPan, YihuiFeng, ZihaoChen, ZhenhuaChen, WeiLuo, JunhangCao, Jiazheng
- [50] Early predictive factors and biomarkers for the response to immunological checkpoint inhibitors (anti-PD-1 and anti-PD-L1)ONCOLOGIE, 2016, 18 (9-10) : 533 - 542Colle, E.Andre, T.Lebbe, C.Borg, C.